Prices of Dukarb, Rosuzet cut 3 yrs through PVA
By Lee, Tak-Sun | translator Kang, Shin-Kook
24.08.30 05:57:07
가나다라
0
Products show strong performance for 3 years... price cut rate reduced by 30% for Korean innovative pharmaceutical companies
According to the industry on the 28th, 6 drugs, including Boryung Pharmaceutical’s 'Dukarb', Dong-A ST 'Growtropin II Inj’, Hanmi Pharmaceutical’s 'Rosuzet Tab', Janssen Korea’s 'Concerta Oros ER Tab’, Boehringer Ingelheim ‘Jardiance Duo Tab', and Daewoong Bio’s ‘Gliatamin’, have had their insurance price ceiling lowered for 3 consecutive years from 2022 to 2024 through the price-volume agreement Type C negotiations.
In this year's Type C negotiations, the prices of Boryung’s four Dukarb Tab items, which are combination antihypertensive drugs, w
Lee, Tak-Sun(hooggasi2@dailypharm.com)
If you want to see the full article, please JOIN US (click)